Gemcitabine by Actavis Pharma, Inc. GEMCITABINE injection

Gemcitabine by

Drug Labeling and Warnings

Gemcitabine by is a Prescription medication manufactured, distributed, or labeled by Actavis Pharma, Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1  INDICATIONS AND USAGE

    1.1 Ovarian Cancer

    Gemcitabine injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.

    1.2 Breast Cancer

    Gemcitabine injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.

    1.3 Non-Small Cell Lung Cancer

    Gemcitabine injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC).

    1.4 Pancreatic Cancer

    Gemcitabine injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine injection is indicated for patients previously treated with fluorouracil.

  • 2  DOSAGE AND ADMINISTRATION

    2.1 Ovarian Cancer

    Recommended Dose and Schedule

    The recommended dosage of gemcitabine injection is 1000 mg/m2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle, in combination with carboplatin AUC 4 administered intravenously on Day 1 after gemcitabine injection administration. Refer to carboplatin prescribing information for additional information.

    Dosage Modifications

    Recommended dosage modifications for gemcitabine injection for myelosuppression are described in Tables 1 and 2 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].

    Table 1: Recommended Dosage Modifications for Gemcitabine Injection for Myelosuppression on Day of Treatment in Ovarian Cancer

    Treatment Day

    Absolute Neutrophil Count
    (x 106/L)

    Platelet Count
    (x 106/L)

    Dosage Modification

    Day 1

    Greater than or equal to 1500

    And

    Greater than or equal to 100,000

    None

    Less than 1500

    Or

    Less than 100,000

    Delay Treatment Cycle

    Day 8

    Greater than or equal to 1500

    And

    Greater than or equal to 100,000

    None

    1000 to 1499

    Or

    75,000 to 99,999

    50% of full dose

    Less than 1000

    Or

    Less than 75,000

    Hold

    Table 2: Recommended Dosage Modifications for Gemcitabine Injection for Myelosuppression in Previous Cycle in Ovarian Cancer

    Occurrence

    Myelosuppression During Treatment Cycle

    Dose Modification

    Initial Occurrence

    • Absolute neutrophil count less than 500 x 106/L for more than 5 days or
    • Absolute neutrophil count less than 100 x 106/L for more than 3 days or
    • Febrile neutropenia or
    • Platelets less than 25,000x106/L or
    • Cycle delay for more than one week due to toxicity

    Permanently reduce Gemcitabine injection to 800 mg/m2 on Days 1 and 8

    Subsequent Occurrence

    If any of the above toxicities occur after the initial dose reduction:

    Permanently reduce Gemcitabine injection to 800 mg/m2 on Day 1 only

    2.2 Breast Cancer

    Recommended Dose and Schedule

    The recommended dosage of gemcitabine injection is 1250 mg/m2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with paclitaxel 175 mg/m2 administered as a 3-hour intravenous infusion on Day 1 before gemcitabine injection administration. Refer to paclitaxel prescribing information for additional information.

    Dosage Modifications

    Recommended dosage modifications for gemcitabine injection for myelosuppression are described in Table 3 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].

    Table 3: Recommended Dosage Modifications for Gemcitabine Injection for Myelosuppression on Day of Treatment in Breast Cancer

    Treatment Day

    Absolute NeutrophilCount

    (x 106/L)

    Platelet Count

    (x 106/L)

    Dosage Modification

    Day 1

    Greater than or equal to 1500

    And

    Greater than or equal to 100,000

    None

    Less than 1500

    Or

    Less than 100,000

    Hold

    Day 8

    Greater than or equal to 1200

    And

    Greater than 75,000

    None

    1000 to 1199

    Or

    50,000 to 75,000

    75% of full dose

    700 to 999

    And

    Greater than or equal to 50,000

    50% of full dose

    Less than 700

    Or

    Less than 50,000

    Hold

    2.3 Non-Small Cell Lung Cancer

    Recommended Dose and Schedule

    28-day schedule

    The recommended dosage of gemcitabine injection is 1000 mg/m2 intravenously over 30 minutes on Days 1, 8, and 15 of each 28-day cycle in combination with cisplatin 100 mg/m2 administered intravenously on Day 1 after gemcitabine injection administration.

    21-day schedule

    The recommended dosage of gemcitabine injection is 1250 mg/m2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with cisplatin 100 mg/m2 administered intravenously on Day 1 after gemcitabine injection administration.

    Refer to cisplatin prescribing information for additional information.

    Dosage Modifications

    Recommended dosage modifications for gemcitabine injection myelosuppression are described in Table 4 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].

    2.4 Pancreatic Cancer

    Recommended Dose and Schedule

    The recommended dosage of gemcitabine injection is 1000 mg/m2 intravenously over 30 minutes. The recommended treatment schedule is as follows:

    • Weeks 1 to 8: weekly dosing for the first 7 weeks followed by one-week rest.
    • After week 8: weekly dosing on Days 1, 8, and 15 of each 28-day cycle.

    Dosage Modifications

    Recommended dosage modifications for gemcitabine injection for myelosuppression are described in Table 4 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].

    Table 4: Recommended Dosage Modifications for Gemcitabine Injection for Myelosuppression in Pancreatic Cancer and Non-Small Cell Lung Cancer
    Absolute Neutrophil Count
    (x 106/L)    		Platelet Count
    (x 106/L)    		Dosage Modification
    Greater than or equal to 1000 AndGreater than or equal to 100,000None
    500 to 999 Or50,000 to 99,99975% of full dose
    Less than 500 OrLess than 50,000Hold

    2.5 Dose Modifications for Non-Hematologic Adverse Reactions

    Permanently discontinue gemcitabine injection for any of the following:

    • Unexplained dyspnea or evidence of severe pulmonary toxicity [see Warnings and Precautions (5.3)]
    • Hemolytic uremic syndrome (HUS) or severe renal impairment [see Warnings and Precautions (5.4)]
    • Severe hepatic toxicity [see Warnings and Precautions (5.5)]
    • Capillary leak syndrome (CLS) [see Warnings and Precautions (5.8)]
    • Posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions (5.9)]

    Withhold gemcitabine injection or reduce dose by 50% for other Grade 3 or 4 non-hematological adverse reactions until resolved. No dose modifications are recommended for alopecia, nausea, or vomiting.

    2.6 Preparation

    Gemcitabine injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 Exercise caution and wear gloves when preparing gemcitabine injection solutions. Immediately wash the skin thoroughly or rinse the mucosa with copious amounts of water if gemcitabine injection contacts the skin or mucus membranes. Death has occurred in animal studies due to dermal absorption.


    Preparation for Intravenous Infusion Administration

    • Withdraw the calculated dose from the vial and discard any unused portion.
    • Prior to administration, dilute the appropriate amount of drug with 0.9% sodium chloride injection to a minimum final concentration of at least 0.1 mg/mL.
    • Store diluted gemcitabine injection solution for no more than 24 hours at controlled room temperature of 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Discard if not used within 24 hours after dilution.
    • Visually inspect for particulate matter or discoloration prior to administration and discard if particulate matter or discoloration is observed.
    • No incompatibilities have been observed with infusion bottles or polyvinyl chloride bags and administration sets.
  • 3  DOSAGE FORMS AND STRENGTHS

    Injection: 200 mg/5.26 mL (38 mg/mL), 1 g/26.3 mL (38 mg/mL), and 2 g/52.6 mL (38 mg/mL) as a clear and colorless to light straw-colored solution in a single-dose vial.

  • 4  CONTRAINDICATIONS

    Gemcitabine injection is contraindicated in patients with a known hypersensitivity to gemcitabine. Reactions include anaphylaxis [see Adverse Reactions (6. 1)].

  • 5  WARNINGS AND PRECAUTIONS

    5.1 Schedule-Dependent Toxicity 

    In clinical trials evaluating the maximum tolerated dose of gemcitabine, prolongation of the infusion time beyond 60 minutes or more frequent than weekly dosing resulted in an increased incidence of clinically significant hypotension, severe flu-like symptoms, myelosuppression, and asthenia. The half-life of gemcitabine is influenced by the length of the infusion [see Clinical Pharmacology (12.3)]. Refer to the recommended gemcitabine injection dosage [see Dosage and Administration (2.1, 2.2, 2.3, 2.4)].

    5.2 Myelosuppression 

    Myelosuppression manifested by neutropenia, thrombocytopenia, and anemia, occurs with gemcitabine as a single agent and the risks are increased when gemcitabine is combined with other cytotoxic drugs. In clinical trials, Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 25%, 8%, and 5%, respectively of the 979 patients who received single agent gemcitabine. The frequencies of Grade 3-4 neutropenia, anemia, and thrombocytopenia varied from 48% to 71%, 8% to 28%, and 5% to 55%, respectively, in patients receiving gemcitabine in combination with another drug [see Adverse Reactions (6.1)].

    Prior to each dose of gemcitabine injection, obtain a complete blood count (CBC) with a differential and a platelet count. Modify the dosage as recommended [see Dosage and Administration (2.1, 2.2, 2.3, 2.4)].

    5.3 Pulmonary Toxicity and Respiratory Failure

    Pulmonary toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS), has been reported. In some cases, these pulmonary events can lead to fatal respiratory failure despite the discontinuation of therapy. The onset of pulmonary symptoms may occur up to 2 weeks after the last dose of gemcitabine [see Adverse Reactions (6.1, 6.2)].

    Permanently discontinue gemcitabine injection in patients who develop unexplained dyspnea, with or without bronchospasm, or evidence of severe pulmonary toxicity.

    5.4 Hemolytic Uremic Syndrome 

    Hemolytic uremic syndrome (HUS), including fatalities from renal failure or the requirement for dialysis, can occur with gemcitabine. In clinical trials, HUS occurred in 0.25% of 2429 patients. Most fatal cases of renal failure were due to HUS [see Adverse Reactions (6.1)]. Serious cases of thrombotic microangiopathy (TMA) other than HUS have been reported with gemcitabine [see Adverse Reactions (6.2)].

    Assess renal function prior to initiation of gemcitabine injection and periodically during treatment. Consider the diagnosis of HUS in patients who develop anemia with evidence of microangiopathic hemolysis; increased bilirubin or LDH; reticulocytosis; severe thrombocytopenia; or evidence of renal failure (increased serum creatinine or BUN). Permanently discontinue gemcitabine injection in patients with HUS or severe renal impairment. Renal failure may not be reversible even with the discontinuation of therapy.

    5.5 Hepatic Toxicity

    Drug-induced liver injury, including liver failure and death, has been reported in patients receiving gemcitabine alone or with other potentially hepatotoxic drugs [see Adverse Reactions (6.1, 6.2)]. Administration of gemcitabine in patients with concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism, or liver cirrhosis can lead to exacerbation of the underlying hepatic insufficiency.

    Assess hepatic function prior to initiation of gemcitabine injection and periodically during treatment. Permanently discontinue gemcitabine injection in patients who develop severe hepatic toxicity.

    5.6 Embryo-Fetal Toxicity 

    Based on animal data and its mechanism of action, gemcitabine injection can cause fetal harm when administered to a pregnant woman. Gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits.

    Advise pregnant women of the potential risk to a fetus.

    Advise females of reproductive potential to use effective contraception during treatment with gemcitabine injection and for 6 months after the final dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with gemcitabine injection and for 3 months following the final dose [see Use in Specific Populations (8.1, 8.3)].

    5.7 Exacerbation of Radiation Therapy Toxicity

    Gemcitabine is not recommended for use in combination with radiation therapy.

    Concurrent (given together or ≤7 days apart)

    Life-threatening mucositis, especially esophagitis and pneumonitis occurred in a trial in which gemcitabine was administered at a dose of 1000 mg/m2 to patients with non-small cell lung cancer for up to 6 consecutive weeks concurrently with thoracic radiation.

    Non-concurrent (given >7 days apart)

    Excessive toxicity has not been observed when gemcitabine is administered more than 7 days before or after radiation. Radiation recall has been reported in patients who received gemcitabine after prior radiation.

    5.8 Capillary Leak Syndrome

    Capillary leak syndrome (CLS) with severe consequences has been reported in patients receiving gemcitabine as a single agent or in combination with other chemotherapeutic agents [see Adverse Reactions (6.2)]. Permanently discontinue gemcitabine injection if CLS develops during therapy.

    5.9 Posterior Reversible Encephalopathy Syndrome

    Posterior reversible encephalopathy syndrome (PRES) has been reported in patients receiving gemcitabine as a single agent or in combination with other chemotherapeutic agents [see Adverse Reactions (6.2)]. PRES can present with headache, seizure, lethargy, hypertension, confusion, blindness, and other visual and neurologic disturbances. Confirm the diagnosis of PRES with magnetic resonance imaging (MRI). Permanently discontinue gemcitabine injection if PRES develops during therapy.

  • 6  ADVERSE REACTIONS

    The following clinically significant adverse reactions are described elsewhere in the labeling:

    • Hypersensitivity [see Contraindications (4)]
    • Schedule-Dependent Toxicity [see Warnings and Precautions (5.1)]
    • Myelosuppression [see Warnings and Precautions (5.2)]
    • Pulmonary Toxicity and Respiratory Failure [see Warnings and Precautions (5.3)]
    • Hemolytic Uremic Syndrome [see Warnings and Precautions (5.4)]
    • Hepatic Toxicity [see Warnings and Precautions (5.5)]
    • Exacerbation of Radiation Therapy Toxicity [see Warnings and Precautions (5.7)]
    • Capillary Leak Syndrome [see Warnings and Precautions (5.8)]
    • Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.9)]

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    Single Agent

    The data described below reflect exposure to gemcitabine as a single agent administered at doses between 800 mg/m2 to 1250 mg/m2 intravenously over 30 minutes once weekly, in 979 patients with various malignancies. The most common (≥20%) adverse reactions of single agent gemcitabine are nausea/vomiting, anemia, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and edema. The most common (≥5%) Grade 3 or 4 adverse reactions were neutropenia, nausea/vomiting, increased ALT, increased alkaline phosphatase, anemia, increased AST, and thrombocytopenia. Approximately 10% of the 979 patients discontinued gemcitabine due to adverse reactions. Adverse reactions resulting in discontinuation of gemcitabine in 2% of 979 patients were cardiovascular adverse reactions (myocardial infarction, cerebrovascular accident, arrhythmia, and hypertension) and adverse reactions resulting in discontinuation of gemcitabine in <1% of 979 patients were anemia, thrombocytopenia, hepatic dysfunction, renal dysfunction, nausea/vomiting, fever, rash, dyspnea, hemorrhage, infection, stomatitis, somnolence, flu-like syndrome, and edema.

    Tables 5 and 6 present the incidence of selected adverse reactions and laboratory abnormalities reported in patients with various malignancies receiving single agent gemcitabine across 5 clinical trials. Additional clinically significant adverse reactions are provided following Table 6.

    Table 5: Selected Adverse Reactions Occurring in ≥10% of Patients Receiving Single Agent Gemcitabinea

    Adverse ReactionsbGemcitabinec
    All Grades
    (%)

    Grade 3

    (%)

    Grade 4

    (%)
    Nausea and Vomiting69131
    Fever4120
    Rash30<10
    Dyspnea233<1
    Diarrhea1910
    Hemorrhage17<1<1
    Infection161<1
    Alopecia15<10
    Stomatitis11<10
    Somnolence11<1<1
    Paresthesias10<10

    a Grade based on criteria from the World Health Organization (WHO).

    b For approximately 60% of patients, non-laboratory adverse events were graded only if assessed to be possibly drug-related.

    c N=699 to 974; all patients with laboratory or non-laboratory data.

    Table 6: Selected Laboratory Abnormalities Occurring in Patients Receiving Single Agent Gemcitabinea

    Laboratory Abnormalityb

    Gemcitabinec

    All Grades
    (%)

    Grade 3
    (%)

    Grade 4
    (%)

    Hematologic

    Anemia

    68

    7

    1

    Neutropenia

    63

    19

    6

    Thrombocytopenia

    24

    4

    1

    Hepatic

    Increased ALT

    68

    8

    2

    Increased AST

    67

    6

    2

    Increased Alkaline Phosphatase

    55

    7

    2

    Hyperbilirubinemia

    13

    2

    <1

    Renal

    Proteinuria

    45

    <1

    0

    Hematuria

    35

    <1

    0

    Increased BUN

    16

    0

    0

    Increased Creatinine

    8

    <1

    0

    a Grade based on criteria from the World Health Organization (WHO).

    b Regardless of causality.

    c N=699 to 974; all patients with laboratory or non-laboratory data.

    Additional adverse reactions include the following:

    • Transfusion requirements: Red blood cell transfusions (19%); platelet transfusions (<1%)

    • Edema: Edema (13%), peripheral edema (20%), generalized edema (<1%)

    • Flu-like symptoms: Fever, asthenia, anorexia, headache, cough, chills, myalgia, asthenia insomnia, rhinitis, sweating and/or malaise (19%)

    • Infection: Sepsis (<1%)

    • Extravasation: Injection-site reactions (4%)

    • Allergic: Bronchospasm (<2%); anaphylactoid reactions

    Ovarian Cancer

    Tables 7 and 8 present the incidence of selected adverse reactions and laboratory abnormalities, occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine with carboplatin arm, reported in a randomized trial (Study 1) of gemcitabine with carboplatin (n=175) compared to carboplatin alone (n=174) for the second-line treatment of ovarian cancer in women with disease that had relapsed more than 6 months following first-line platinum-based chemotherapy [see Clinical Studies (14.1)]. Additional clinically significant adverse reactions, occurring in <10% of patients, are provided following Table 8.

    The proportion of patients with dose adjustments for carboplatin (1.8% versus 3.8%), doses of carboplatin omitted (0.2% versus 0) and discontinuing treatment for adverse reactions (11% versus 10%), were similar between arms. Dose adjustment for gemcitabine occurred in 10% of patients and gemcitabine dose was omitted in 14% of patients in the gemcitabine/carboplatin arm.

    Table 7: Adverse Reactions Occurring in >10% of Patients Receiving Gemcitabine with Carboplatin and at Higher Incidence than in Patients Receiving Single Agent Carboplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 1a

    Adverse Reactionsb

    Gemcitabine/Carboplatin (N=175)

    Carboplatin
    (N=174)

    All Grades (%)

    Grade 3 (%)

    Grade 4 (%)

    All Grades (%)

    Grade 3 (%)

    Grade 4 (%)

    Nausea

    69

    6

    0

    61

    3

    0

    Alopecia

    49

    0

    0

    17

    0

    0

    Vomiting

    46

    6

    0

    36

    2

    <1

    Constipation

    42

    6

    1

    37

    3

    0

    Fatigue

    40

    3

    <1

    32

    5

    0

    Diarrhea

    25

    3

    0

    14

    <1

    0

    Stomatitis/Pharyngitis

    22

    <1

    0

    13

    0

    0

    a Grade based on National Cancer Institute CTC Version 2.0.

    b Regardless of causality.

    Table 8: Laboratory Abnormalities Occurring in Patients Receiving Gemcitabine with Carboplatin and at Higher Incidence than in Patients Receiving Single Agent Carboplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 1a

    Laboratory Abnormalityb

    Gemcitabine/Carboplatin (N=175)

    Carboplatin
    (N=174)

    All Grades (%)

    Grade 3
    (%)

    Grade 4
    (%)

    All Grades (%)

    Grade 3
    (%)

    Grade 4
    (%)

    Hematologic

    Neutropenia

    90

    42

    29

    58

    11

    1

    Anemia

    86

    22

    6

    75

    9

    2

    Thrombocytopenia

    78

    30

    5

    57

    10

    1

    RBC Transfusionsc

    38

    ­-

    -

    15

    -

    -

    Platelet Transfusionsc

    9

    -

    -

    3

    -

    -

    a Grade based on National Cancer Institute CTC Version 2.0.

    b Regardless of causality.

    c Percent of patients receiving transfusions. Transfusions are not CTC-graded events. Blood transfusions included both packed red
      blood cells and whole blood. 

    Hematopoietic growth factors were administered more frequently in the gemcitabine-containing arm: leukocyte growth factor (24% and 10%) and erythropoiesis-stimulating agent (7% and 3.9%).

    The following clinically relevant Grade 3 and 4 adverse reactions occurred more frequently in the gemcitabine with carboplatin arm: dyspnea (3.4% versus 2.9%), febrile neutropenia (1.1% versus 0), hemorrhagic event (2.3% versus 1.1 %), motor neuropathy (1.1% versus 0.6%), and rash/desquamation (0.6% versus 0).

    Breast Cancer

    Tables 9 and 10 present the incidence of selected adverse reactions and laboratory abnormalities, occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine with paclitaxel arm, reported in a randomized trial (Study 2) of gemcitabine with paclitaxel (n=262) compared to paclitaxel alone (n=259) for the first-line treatment of metastatic breast cancer (MBC) in women who received anthracycline-containing chemotherapy in the adjuvant/neo­adjuvant setting or for whom anthracyclines were contraindicated [see Clinical Studies (14.2)]. Additional clinically significant adverse reactions, occurring in <10% of patients, are provided following Table 10.

    The requirement for dose reduction of paclitaxel were higher for patients in the gemcitabine/paclitaxel arm (5% versus 2%). The number of paclitaxel doses omitted (<1%), the proportion of patients discontinuing treatment for adverse reactions (7% versus 5%) and the number of treatment-related deaths (1 patient in each arm) were similar between the two arms.

    Table 9: Selected Adverse Reactions Occurring in Patients Receiving Gemcitabine with Paclitaxel and at Higher Incidence than in Patients Receiving Single Agent Paclitaxel [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 2a

    Adverse Reactionsb

    Gemcitabine/Paclitaxel (N=262)

    Paclitaxel
    (N=259)

    All Grades (%)

    Grade 3
    (%)

    Grade 4 (%)

    All Grades (%)

    Grade 3
    (%)

    Grade 4
    (%)

    Alopecia

    90

    14

    4

    92

    19

    3

    Neuropathy-Sensory

    64

    5

    <1

    58

    3

    0

    Nausea

    50

    1

    0

    31

    2

    0

    Fatigue

    40

    6

    <1

    28

    1

    <1

    Vomiting

    29

    2

    0

    15

    2

    0

    Diarrhea

    20

    3

    0

    13

    2

    0

    Anorexia

    17

    0

    0

    12

    <1

    0

    Neuropathy-Motor

    15

    2

    <1

    10

    <1

    0

    Stomatitis/Pharyngitis

    13

    1

    <1

    8

    <1

    0

    Fever

    13

    <1

    0

    3

    0

    0

    Rash/Desquamation

    11

    <1

    <1

    5

    0

    0

    Febrile Neutropenia

    6

    5

    <1

    2

    1

    0

    a Grade based on National Cancer Institute CTC Version 2.0.

    b Non-laboratory events were graded only if assessed to be possibly drug-related.

    Table 10: Selected Laboratory Abnormalities Occurring in >10% of Patients Receiving Gemcitabine with Paclitaxel and at a Higher Incidence than Patients Receiving Single Agent Paclitaxel [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 2a

    Laboratory Abnormalityb

    Gemcitabine/Paclitaxel (N=262)

    Paclitaxel
    (N=259)

    All Grades (%)

    Grade 3
    (%)

    Grade 4
    (%)

    All Grades (%)

    Grade 3
    (%)

    Grade 4
    (%)

    Hematologic

    Anemia

    69

    6

    1

    51

    3

    <1

    Neutropenia

    69

    31

    17

    31

    4

    7

    Thrombocytopenia

    26

    5

    <1

    7

    <1

    <1

    Hepatobiliary

    Increased ALT

    18

    5

    <1

    6

    <1

    0

    Increased AST

    16

    2

    0

    5

    <1

    0

    a Grade based on National Cancer Institute CTC Version 2.0.

    b Regardless of causality.

    Clinically relevant Grade 3 or 4 dyspnea occurred with a higher incidence in the gemcitabine with paclitaxel arm compared with the paclitaxel arm (1.9% versus 0).

    Non-Small Cell Lung Cancer

    Tables 11 and 12 present the incidence of selected adverse reactions and laboratory abnormalities occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine with cisplatin arm, reported in a randomized trial (Study 3) of gemcitabine with cisplatin (n=260) administered in 28-day cycles as compared to cisplatin alone (n=262) in patients receiving first-line treatment for locally advanced or metastatic NSCLC [see Clinical Studies (14.3)].

    Patients randomized to gemcitabine with cisplatin received a median of 4 cycles of treatment and those randomized to cisplatin alone received a median of 2 cycles of treatment. In this trial, the requirement for dose adjustments (>90% versus 16%), discontinuation of treatment for adverse reactions (15% versus 8%), and the proportion of patients hospitalized (36% versus 23%) were all higher for patients receiving gemcitabine with cisplatin compared to those receiving cisplatin alone. The incidence of febrile neutropenia (3% versus <1%), sepsis (4% versus 1%), Grade 3 cardiac dysrhythmias (3% versus <1%) were all higher in the gemcitabine with cisplatin arm compared to the cisplatin alone arm. The two-drug combination was more myelosuppressive with 4 (1.5%) possibly treatment-related deaths, including 3 resulting from myelosuppression with infection and one case of renal failure associated with pancytopenia and infection. No deaths due to treatment were reported on the cisplatin arm.

    Table 11: Selected Adverse Reactions Occurring in ≥10% of Patients Receiving Gemcitabine with Cisplatin and at Higher Incidence than in Patients Receiving Single Agent Cisplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 3a

    Adverse Reactionsb

    Gemcitabine/Cisplatinc

    Cisplatind

    All Grades (%)

    Grade 3
    (%)

    Grade 4 (%)

    All Grades
    (%)

    Grade 3
    (%)

    Grade 4
    (%)

    Nausea

    93

    25

    2

    87

    20

    <1

    Vomiting

    78

    11

    12

    71

    10

    9

    Alopecia

    53

    1

    0

    33

    0

    0

    Neuro Motor

    35

    12

    0

    15

    3

    0

    Diarrhea

    24

    2

    2

    13

    0

    0

    Neuro Sensory

    23

    1

    0

    18

    1

    0

    Infection

    18

    3

    2

    12

    1

    0

    Fever

    16

    0

    0

    5

    0

    0

    Neuro Cortical

    16

    3

    1

    9

    1

    0

    Neuro Mood

    16

    1

    0

    10

    1

    0

    Local

    15

    0

    0

    6

    0

    0

    Neuro Headache

    14

    0

    0

    7

    0

    0

    Stomatitis

    14

    1

    0

    5

    0

    0

    Hemorrhage

    14

    1

    0

    4

    0

    0

    Hypotension

    12

    1

    0

    7

    1

    0

    Rash

    11

    0

    0

    3

    0

    0

    a Grade based on National Cancer Institute Common Toxicity Criteria (CTC).

    b Non-laboratory events were graded only if assessed to be possibly drug-related.

    c N=217 to 253; all gemcitabine/cisplatin patients with laboratory or non-laboratory data

    d N=213 to 248; all cisplatin patients with laboratory or non-laboratory data

    Table 12: Selected Laboratory Abnormalities Occurring in >10% of Patients Receiving Gemcitabine with Cisplatin and at Higher Incidence than in Patients Receiving Single Agent Cisplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 3a

    Laboratory Abnormalityb

    Gemcitabine/Cisplatinc

    Cisplatind

    All Grades (%)

    Grade 3 (%)

    Grade 4 (%)

    All Grades (%)

    Grade 3 (%)

    Grade 4 (%)

    Hematologic

    Anemia

    89

    22

    3

    67

    6

    1

    Thrombocytopenia

    85

    25

    25

    13

    3

    1

    Neutropenia

    79

    22

    35

    20

    3

    1

    Lymphopenia

    75

    25

    18

    51

    12

    5

    RBC Transfusionse

    39

    -

    -

    13

    -

    -

    Platelet Transfusionse

    21

    -

    -

    <1

    -

    -

    Hepatic

    Increased Transaminases

    22

    2

    1

    10

    1

    0

    Increased Alkaline Phosphatase

    19

    1

    0

    13

    0

    0

    Renal

    Increased Creatinine

    38

    4

    <1

    31

    2

    <1

    Proteinuria

    23

    0

    0

    18

    0

    0

    Hematuria

    15

    0

    0

    13

    0

    0

    Other Laboratory

    Hyperglycemia

    30

    4

    0

    23

    3

    0

    Hypomagnesemia

    30

    4

    3

    17

    2

    0

    Hypocalcemia

    18

    2

    0

    7

    0

    <1

    a Grade based on National Cancer Institute CTC.

    b Regardless of causality.

    c N=217 to 253; all gemcitabine/cisplatin patients with laboratory or non-laboratory data

    d N=213 to 248; all cisplatin patients with laboratory or non-laboratory data

    e Percent of patients receiving transfusions. Percent transfusions are not CTC-graded events.

    Tables 13 and 14 present the incidence of selected adverse reactions and laboratory abnormalities occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine with cisplatin arm, reported in a randomized trial (Study 4) of gemcitabine with cisplatin (n=69) administered in 21-day cycles as compared to etoposide with cisplatin (n=66) in patients receiving first-line treatment for locally advanced or metastatic NSCLC [see Clinical Studies (14.3)]. Additional clinically significant adverse reactions are provided following Table 14.

    Patients in the gemcitabine/cisplatin (GC) arm received a median of 5 cycles and those in the etoposide/cisplatin (EC) arm received a median of 4 cycles. The majority of patients receiving more than one cycle of treatment required dose adjustments; 81% in the GC arm and 68% in the EC arm. The incidence of hospitalizations for adverse reactions was 22% in the GC arm and 27% in the EC arm. The proportion of patients who discontinued treatment for adverse reactions was higher in the GC arm (14% versus 8%). The proportion of patients who were hospitalized for febrile neutropenia was lower in the GC arm (7% versus 12%). There was one death attributed to treatment, a patient with febrile neutropenia and renal failure, which occurred in the GC arm.

    Table 13: Selected Adverse Reactions in Patients Receiving Gemcitabine with Cisplatin in Study 4a

    Adverse Reactionsb

    Gemcitabine/Cisplatinc

    Etoposide/Cisplatind

    All Grades (%)

    Grade 3 (%)

    Grade 4 (%)

    All Grades (%)

    Grade 3 (%)

    Grade 4 (%)

    Nausea and Vomiting

    96

    35

    4

    86

    19

    7

    Alopecia

    77

    13

    0

    92

    51

    0

    Paresthesias

    38

    0

    0

    16

    2

    0

    Infection

    28

    3

    1

    21

    8

    0

    Stomatitis

    20

    4

    0

    18

    2

    0

    Diarrhea

    14

    1

    1

    13

    0

    2

    Edemae

    12

    -

    -

    2

    -

    -

    Rash

    10

    0

    0

    3

    0

    0

    Hemorrhage

    9

    0

    3

    3

    0

    3

    Fever

    6

    0

    0

    3

    0

    0

    Somnolence

    3

    0

    0

    3

    2

    0

    Flu-like Syndromee

    3

    -

    -

    0

    -

    -

    Dyspnea

    1

    0

    1

    3

    0

    0

    a Grade based on criteria from the WHO.

    b Non-laboratory events were graded only if assessed to be possibly drug-related. Pain data were not collected.

    c N=67 to 69; all gemcitabine/cisplatin patients with laboratory or non-laboratory data.

    d N=57 to 63; all etoposide/cisplatin patients with laboratory or non-laboratory data.

    e Flu-like syndrome and edema were not graded.

    Table 14: Selected Laboratory Abnormalities Occurring in Patients Receiving Gemcitabine with Cisplatin in Study 4a

    Laboratory Abnormalityb

    Gemcitabine/Cisplatinc

    Etoposide/Cisplatind

    All Grades (%)

    Grade 3 (%)

    Grade 4 (%)

    All Grades (%)

    Grade 3 (%)

    Grade 4 (%)

    Hematologic

    Anemia

    88

    22

    0

    77

    13

    2

    Neutropenia

    88

    36

    28

    87

    20

    56

    Thrombocytopenia

    81

    39

    16

    45

    8

    5

    RBC Transfusionsc

    29

    -

    -

    21

    -

    -

    Platelet Transfusionse

    3

    -

    -

    8

    -

    -

    Hepatic

    Increased Alkaline Phosphatase

    16

    0

    0

    11

    0

    0

    Increased ALT

    6

    0

    0

    12

    0

    0

    Increased AST

    3

    0

    0

    11

    0

    0

    Renal

    Hematuria

    22

    0

    0

    10

    0

    0

    Proteinuria

    12

    0

    0

    5

    0

    0

    Increased BUN

    6

    0

    0

    4

    0

    0

    Increased Creatinine

    2

    0

    0

    2

    0

    0

    a Grade based on criteria from the WHO.

    b Regardless of causality.

    c N=67 to 69; all gemcitabine/cisplatin patients with laboratory or non-laboratory data.

    d N=57 to 63; all etoposide/cisplatin patients with laboratory or non-laboratory data.

    e WHO grading scale not applicable to proportion of patients with transfusions.

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during post-approval use of gemcitabine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Blood and Lymphatic System: TMA

    Cardiovascular: Congestive heart failure, myocardial infarction, arrhythmias, supraventricular arrhythmias

    Vascular: Peripheral vasculitis, gangrene, capillary leak syndrome

    Skin: Cellulitis, pseudocellulitis, severe skin reactions, including desquamation and bullous skin eruptions

    Hepatic: Hepatic failure, hepatic veno-occlusive disease

    Pulmonary: Interstitial pneumonitis, pulmonary fibrosis, pulmonary eosinophilia, pulmonary edema, adult respiratory distress syndrome (ARDS)

    Nervous System: Posterior reversible encephalopathy syndrome (PRES)

  • 8  USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Based on animal data and its mechanism of action, gemcitabine injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on the use of gemcitabine in pregnant women. In animal reproduction studies, gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits (see Data). Advise pregnant women of the potential risk to a fetus [see Use in Specific Populations (8.3)].

    In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    Data

    Animal Data

    Gemcitabine is embryotoxic in mice. Daily dosing of gemcitabine to pregnant mice increased the incidence of fetal malformations (cleft palate, incomplete ossification) at doses of 1.5 mg/kg/day [about 0.005 times the 1000 mg/m2 clinical dose based on body surface area (BSA)]. Gemcitabine is embryotoxic and fetotoxic in rabbits. Daily dosing of gemcitabine to pregnant rabbits resulted in fetotoxicity (decreased fetal viability, reduced litter sizes and developmental delays) and increased the incidence of fetal malformations (fused pulmonary artery, absence of gall bladder) at doses of 0.1 mg/kg/day (about 0.002 times the 1000 mg/m2 clinical dose based on BSA).

    8.2 Lactation  

    Risk Summary

    There is no information regarding the presence of gemcitabine or its metabolites in human milk, or their effects on the breastfed infant or on milk production. Due to the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with gemcitabine injection and for at least one week following the last dose.

    8.3 Females and Males of Reproductive Potential

    Pregnancy Testing

    Verify pregnancy status in females of reproductive potential prior to initiating gemcitabine injection [see Use in Specific Populations (8.1)].

    Contraception

    Gemcitabine injection can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

    Females

    Because of the potential for genotoxicity, advise females of reproductive potential to use effective contraception during treatment with gemcitabine injection and for 6 months after the final dose.

    Males

    Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use effective contraception during treatment with gemcitabine injection and for 3 months after the final dose [see Nonclinical Toxicology (13.1)].

    Infertility

    Males

    Based on animal studies, gemcitabine may impair fertility in males of reproductive potential [see Nonclinical Toxicology (13.1)]. It is not known whether these effects on fertility are reversible.


    8.4 Pediatric Use

    The safety and effectiveness of gemcitabine have not been established in pediatric patients.

    The safety and pharmacokinetics of gemcitabine were evaluated in a trial in pediatric patients with refractory leukemia. The maximum tolerated dose was 10 mg/m2/min for 360 minutes weekly for three weeks followed by a one-week rest period.

    The safety and activity of gemcitabine were evaluated in a trial of pediatric patients with relapsed acute lymphoblastic leukemia (22 patients) and acute myelogenous leukemia (10 patients) at a dose of 10 mg/m2/min administered over 360 minutes weekly for three weeks followed by a one-week rest period. Patients with M1 or M2 bone marrow on Day 28 who did not experience unacceptable toxicity were eligible to receive a maximum of one additional four-week course. Toxicities observed included myelosuppression, febrile neutropenia, increased serum transaminases, nausea, and rash/desquamation. No meaningful clinical activity was observed in this trial.

    8.5 Geriatric Use

    In clinical studies which enrolled 979 patients with various malignancies who received single agent gemcitabine, no overall differences in safety were observed between patients aged 65 and older and younger patients, with the exception of a higher rate of Grade 3-4 thrombocytopenia in older patients as compared to younger patients.

    In a randomized trial in women with ovarian cancer (Study 1), 175 women received gemcitabine with carboplatin, of which 29% were age 65 years or older. Similar effectiveness was observed between older and younger women. There was significantly higher Grade 3-4 neutropenia in women 65 years of age or older [see Dosage and Administration (2.1)].

    Gemcitabine clearance is affected by age; however, there are no recommended dose adjustments based on patients' age [see Clinical Pharmacology (12.3)].

    8.6 Gender

    Gemcitabine clearance is decreased in females [see Clinical Pharmacology (12.3)]. In single agent studies of gemcitabine, women, especially older women, were more likely not to proceed to a subsequent cycle and to experience Grade 3-4 neutropenia and thrombocytopenia [see Dosage and Administration (2.1, 2.2, 2.3, 2.4)].

  • 10  OVERDOSAGE

    There is no known antidote for overdoses of gemcitabine. Myelosuppression, paresthesias, and severe rash were the principal toxicities seen when a single dose as high as 5700 mg/m2 was administered by intravenous infusion over 30 minutes every 2 weeks to several patients in a dose-escalation study. In the event of suspected overdose, monitor with appropriate blood counts and provide supportive therapy, as necessary.

  • 11  DESCRIPTION

    Gemcitabine is a nucleoside metabolic inhibitor. The chemical name of gemcitabine hydrochloride, USP is 2´-deoxy-2´,2´-difluorocytidine monohydrochloride (β-isomer). The structural formula is as follows:

    Image from Drug Label Content

    Gemcitabine hydrochloride, USP is a white to off-white solid with a molecular formula of C9H11F2N3O4 HCl and a molecular weight of 299.66 g/mol. It is soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and polar organic solvents.

    Gemcitabine Injection is a sterile solution in single-dose vials for intravenous use. Vials of gemcitabine injection contain either 200 mg, 1 g, or 2 g of gemcitabine hydrochloride, USP (expressed as free base). Each mL contains equivalent of 38 mg of gemcitabine in water for injection. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.

  • 12  CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabine triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the action of the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabine nucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands which eventually results in the initiation of apoptotic cell death.

    12.3 Pharmacokinetics

    The pharmacokinetics of gemcitabine were examined in 353 patients, with various solid tumors. Pharmacokinetic parameters were derived using data from patients treated for varying durations of therapy given weekly with periodic rest weeks and using both short infusions (<70 minutes) and long infusions (70 to 285 minutes). The total gemcitabine dose varied from 500 mg/m2 to 3600 mg/m2.

    Distribution

    The volume of distribution was increased with infusion length. Volume of distribution of gemcitabine was 50 L/m2 following infusions lasting <70 minutes. For long infusions, the volume of distribution rose to 370 L/m2.

    Gemcitabine pharmacokinetics are linear and are described by a 2-compartment model. Population pharmacokinetic analyses of combined single and multiple dose studies showed that the volume of distribution of gemcitabine was significantly influenced by duration of infusion and sex. Gemcitabine plasma protein binding is negligible.

    Elimination

    Metabolism

    The active metabolite, gemcitabine triphosphate, can be extracted from peripheral blood mononuclear cells. The half-life of the terminal phase for gemcitabine triphosphate from mononuclear cells ranges from 1.7 to 19.4 hours.

    Excretion

    Gemcitabine disposition was studied in 5 patients who received a single 1000 mg/m2 of radiolabeled drug as a 30-minute infusion. Within one (1) week, 92% to 98% of the dose was recovered, almost entirely in the urine. Gemcitabine (<10%) and the inactive uracil metabolite, 2´-deoxy-2´,2´-difluorouridine (dFdU), accounted for 99% of the excreted dose. The metabolite dFdU is also found in plasma.

    Specific Populations

    Geriatric Patients

    Clearance of gemcitabine was affected by age. The lower clearance in geriatric patients results in higher concentrations of gemcitabine for any given dose. Differences in either clearance or volume of distribution based on patient characteristics or the duration of infusion result in changes in half-life and plasma concentrations. Table 15 shows plasma clearance and half-life of gemcitabine following short infusions for typical patients by age and sex.

    Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and for long infusions varied from 245 to 638 minutes, depending on age and sex, reflecting a greatly increased volume of distribution with longer infusions.

    Male and Female Patients

    Females have lower clearance and longer half-lives than male patients as described in Table 15.

    Table 15: Gemcitabine Clearance and Half-Life for the “Typical” Patient

    Age

    Clearance Men (L/hr/m2)

    Clearance Women (L/hr/m2)

    Half-Lifea Men (min)

    Half-Lifea Women (min)

    29

    92.2

    69.4

    42

    49

    45

    75.7

    57.0

    48

    57

    65

    55.1

    41.5

    61

    73

    79

    40.7

    30.7

    79

    94

    a Half-life for patients receiving a <70 minute infusion.

    Patients with Renal Impairment

    No clinical studies have been conducted with gemcitabine in patients with decreased renal function.

    Patients with Hepatic Impairment

    No clinical studies have been conducted with gemcitabine in patients with decreased hepatic function.

    Drug Interaction Studies

    When gemcitabine (1250 mg/m2 on Days 1 and 8) and cisplatin (75 mg/m2 on Day 1) were administered in patients with NSCLC, the clearance of gemcitabine on Day 1 was 128 L/hr/m2 and on Day 8 was 107 L/hr/m2. Data from patients with NSCLC demonstrate that gemcitabine and carboplatin given in combination does not alter the pharmacokinetics of gemcitabine or carboplatin compared to administration of either single agent, however, due to wide confidence intervals and small sample size, interpatient variability may be observed.

    Data from patients with metastatic breast cancer shows that gemcitabine has little or no effect on the pharmacokinetics (clearance and half-life) of paclitaxel and paclitaxel has little or no effect on the pharmacokinetics of gemcitabine.

  • 13  NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Long-term animal studies to evaluate the carcinogenic potential of gemcitabine have not been conducted. Gemcitabine was mutagenic in an in vitro mouse lymphoma (L5178Y) assay and was clastogenic in an in vivo mouse micronucleus assay. Gemcitabine intraperitoneal doses of 0.5 mg/kg/day (about 1/700 the 1000 mg/m2 clinical dose based on BSA) in male mice resulted in moderate to severe hypospermatogenesis, decreased fertility, and decreased implantations. In female mice, fertility was not affected but maternal toxicities were observed at 1.5 mg/kg/day administered intravenously (about 1/200 the 1000 mg/m2 clinical dose based on BSA) and fetotoxicity or embryolethality was observed at 0.25 mg/kg/day administered intravenously (about 1/1300 the 1000 mg/m2 clinical dose based on BSA).

  • 14  CLINICAL STUDIES

    14.1 Ovarian Cancer

    The efficacy of gemcitabine was evaluated in a multinational, randomized, open-label trial conducted in women receiving initial treatment for metastatic breast cancer and who have received prior adjuvant/neoadjuvant anthracycline chemotherapy unless clinically contraindicated.

    Patients were randomized to receive gemcitabine 1250 mg/m2 on Days 1 and 8 of each 21-day cycle with paclitaxel 175 mg/m2 administered on Day 1 before gemcitabine administration (n=267) or paclitaxel 175 mg/m2 on Day 1 of each 21-day cycle (n=262). The major efficacy outcome measure was time to documented disease progression.

    A total of 529 patients were enrolled. Demographic and baseline characteristics were similar between treatment arms (Table 18).

    Efficacy results are presented in Table 19 and Figure 2. The addition of gemcitabine to paclitaxel resulted in statistically significant improvement in time to documented disease progression and overall response rate compared to paclitaxel alone. There was no significant difference in overall survival.

    Table 16: Baseline Demographics and Clinical Characteristics for Study 1

    Gemcitabine/Carboplatin (N=178)

    Carboplatin
    (N=178)

    Median age, years

    59

    58

    Range

    36 to 78

    21 to 81

    Baseline ECOG performance status 0 to 1a

    94%

    95%

    Disease Status

    Evaluable

    8%

    3%

    Bidimensionally measurable

    92%

    96%

    Platinum-free intervalb

    6 to 12 months

    40%

    40%

    >12 months

    59%

    60%

    First-line therapy

    Platinum-taxane combination

    70%

    71%

    Platinum-non-taxane combination

    29%

    28%

    Platinum monotherapy

    1%

    1%

    a 5 patients on gemcitabine/carboplatin arm and 4 patients on carboplatin arm had no baseline Eastern Cooperative Oncology Group (ECOG) performance status.

    b 2 on gemcitabine/carboplatin arm and 1 on carboplatin arm had platinum-free interval <6 months.

    Table 17: Efficacy Results in Study 1

    Efficacy Parameter

    Gemcitabine/Carboplatin

    Carboplatin

    (N=178)

    (N=178)

    Progression-Free Survival

    Median (95% CIa) in months

    8.6 (8.0, 9.7)

    5.8 (5.2, 7.1)

    Hazard Ratio (95% CI)

    0.72 (0.57, 0.90)

    p-valueb

    p=0.0038

    Overall Survival

    Median (95% CI) in months

    18.0 (16.2, 20.3)

    17.3 (15.2, 19.3)

    Hazard Ratio (95% CI)

    0.98 (0.78, 1.24)

    p-valueb

    p=0.8977

    Overall Response Rate by

    Investigator Review

    47.2%

    30.9%

    p-valuec

    p=0.0016

    CRd

    14.6%

    6.2%

    PR with PRNMe

    32.6%

    24.7%

    Overall Response Ratef by

    Independent Review

    46.3%

    35.6%

    p-valuec

    p=0.11

    CRd

    9.1%

    4.0%

    PR with PRNMe

    37.2%

    31.7%

    a CI=confidence interval.

    b Log rank, unadjusted.

    c Chi square.

    d CR=Complete response.

    e PR with PRNM=Partial response with partial response, non-measurable disease.

    f Independently reviewed cohort - gemcitabine/carboplatin (n=121), carboplatin (n=101); independent reviewers unable to measure disease detected by sonography or physical exam.

     

    Figure 1: Kaplan-Meier Curves for Progression Free Survival in Study 1

    e6d71634-figure-02

    14.2 Breast Cancer

    The efficacy of gemcitabine was evaluated in a multinational, randomized, open-label trial conducted in women receiving initial treatment for metastatic breast cancer and who have received prior adjuvant/neoadjuvant anthracycline chemotherapy unless clinically contraindicated.

    Patients were randomized to receive gemcitabine 1250 mg/m2 on Days 1 and 8 of each 21-day cycle with paclitaxel 175 mg/m2 administered on Day 1 before gemcitabine administration (n=267) or paclitaxel 175 mg/m2 on Day 1 of each 21-day cycle (n=262). The major efficacy outcome measure was time to documented disease progression.

    A total of 529 patients were enrolled. Demographic and baseline characteristics were similar between treatment arms (Table 18).

    Efficacy results are presented in Table 19 and Figure 2. The addition of gemcitabine to paclitaxel resulted in statistically significant improvement in time to documented disease progression and overall response rate compared to paclitaxel alone. There was no significant difference in overall survival.

    Table 18: Baseline Demographics and Clinical Characteristics for Study 2

    Gemcitabine/Paclitaxel
    (N=267)    		Paclitaxel
    (N=262)
    Median age (years)5352
    Range26 to 8326 to 75
    Metastatic disease97%97%
    Baseline KPSa ≥9070%74%
    Number of tumor sites
    1 to 257%59%
    ≥343%41%
    Visceral disease73%73%
    Prior anthracycline97%96%

    a Karnofsky Performance Status.

    Table 19: Efficacy Results in Study 2

    Efficacy ParameterGemcitabine/Paclitaxel
    (N=267)    		Paclitaxel
    (N=262)
    Time to Documented Disease Progressiona
    Median (95% CI) in months5.2 (4.2, 5.6)2.9 (2.6, 3.7)
    Hazard Ratio (95% CI)0.650 (0.524, 0.805)
    p-valuep<0.0001
    Overall Survivalb
    Median (95% CI) in months18.6 (16.5, 20.7)15.8 (14.1, 17.3)
    Hazard Ratio (95% CI)0.86 (0.71, 1.04)
    p-valueNot Significant
    Overall Response Rate40.8%22.1%
    (95% CI)(34.9, 46.7)(17.1, 27.2)
    p-valuep<0.0001

    a These represent reconciliation of investigator and Independent Review Committee assessments according to a predefined algorithm.

    b Based on the ITT population.

    Figure 2: Kaplan-Meier Curves for Time to Documented Disease Progression in Study 2

    e6d71634-figure-03

    14.3 Non-Small Cell Lung Cancer (NSCLC)

    The efficacy of gemcitabine was evaluated in two randomized, multicenter trials.

    Study 3: 28-Day Schedule

    A multinational, randomized trial (Study 3) compared gemcitabine with cisplatin to cisplatin alone in the treatment of patients with inoperable Stage IIIA, IIIB, or IV NSCLC who had not received prior chemotherapy. Patients were randomized to receive either gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of each 28-day cycle with cisplatin 100 mg/m2 on Day 1 after gemcitabine administration (N=260) or cisplatin 100 mg/m2 on Day 1 of each 28-day cycle (N=262). The major efficacy outcome measure was overall survival.

    A total of 522 patients were enrolled. Demographics and baseline characteristics (Table 20) were similar between arms with the exception of histologic subtype of NSCLC, with 48% of patients on the cisplatin arm and 37% of patients on the gemcitabine with cisplatin arm having adenocarcinoma.

    Efficacy results are presented in Table 21 and Figure 3.

    Study 4: 21-Day Schedule

    A randomized (1:1), multicenter trial (Study 4) was conducted in patients with Stage IIIB or IV NSCLC. Patients were randomized to receive gemcitabine 1250 mg/m2 on Days 1 and 8 of each 21-day cycle with cisplatin 100 mg/m2 on Day 1 after gemcitabine administration or etoposide 100 mg/m2 intravenously on Days 1, 2, and 3 with cisplatin 100 mg/m2 on Day 1 of each 21-day cycle. The major efficacy outcome measure was response rate.

    A total of 135 patients were enrolled. Demographics and baseline characteristics are summarized in Table 20.

    Efficacy results are presented in Table 21. There was no significant difference in survival between the two treatment arms. The median survival was 8.7 months for the gemcitabine with cisplatin arm versus 7 months for the etoposide with cisplatin arm. Median time to disease progression for the gemcitabine with cisplatin arm was 5 months compared to 4.1 months on the etoposide with cisplatin arm (Log rank p=0.015, two-sided). The objective response rate for the gemcitabine with cisplatin arm was 33% compared to 14% on the etoposide with cisplatin arm (Fisher’s Exact p=0.01, two-sided).

    Figure 3: Kaplan-Meier Curves for Overall Survival in Study 3e6d71634-figure-04

    Table 20: Baseline Demographics and Clinical Characteristics for Studies 3 and 4

    Trial

    28-day Schedule (Study 3)

    21-day Schedule (Study 4)

    Gemcitabine/Cisplatin
    (N=260)

    Cisplatin
    (N=262)

    Gemcitabine/Cisplatin
    (N=69)

    Etoposide/Cisplatin
    (N=66)

    Male

    70%

    71%

    93%

    92%

    Median age, years

    62

    63

    58

    60

    Range

    36 to 88

    35 to 79

    33 to 76

    35 to 75

    Stage IIIA

    7%

    7%

    N/Aa

    N/Aa

    Stage IIIB

    26%

    23%

    48%

    52%

    Stage IV

    67%

    70%

    52%

    49%

    Baseline KPSb70 to 80

    41%

    44%

    45%

    52%

    Baseline KPSb 90 to 100

    57%

    55%

    55%

    49%

    aN/A Not applicable.

    bKarnofsky Performance Status.

     

    Table 21: Efficacy Results for Studies 3 and 4

     

    Trial

    28-day Schedule (Study 3)

    21-day Schedule (Study 4)


    Efficacy Parameter

    Gemcitabine/Cisplatin

    (N=260)

    Cisplatin


    (N=262)

    Gemcitabine/Cisplatin

    (N=69)

    Etoposide/Cisplatin


    (N=66)

    Survival

    Median (95% CIa) in months

    9.0 (8.2, 11.0)

    7.6 (6.6, 8.8)

    8.7 (7.8, 10.1)

    7.0 (6.0, 9.7)

    p-valueb

    p=0.008

    p=0.18

    Time to Disease Progression

    Median (95% CIa) in months

    5.2 (4.2, 5.7)

    3.7 (3.0, 4.3)

    5.0 (4.2, 6.4)

    4.1 (2.4, 4.5)

    p-valueb

    p=0.009

    p=0.015

    Tumor Response

    26%

    10%

    33%

    14%

    p-valueb

    p<0.0001

    p=0.01

    a CI=confidence intervals.

    b p-value two-sided Fisher’s Exact test for difference in binomial proportions; log rank test for time-to-event analyses.

    14.4 Pancreatic Cancer

    The efficacy of gemcitabine was evaluated in two trials (Studies 5 and 6), a randomized, single-blind, two-arm, active-controlled trial (Study 5) conducted in patients with locally advanced or metastatic pancreatic cancer who had received no prior chemotherapy and in a single-arm, open-label, multicenter trial (Study 6) conducted in patients with locally advanced or metastatic pancreatic cancer previously treated with fluorouracil or a fluorouracil-containing regimen. In Study 5, patients were randomized to receive either gemcitabine 1000 mg/m2 intravenously over 30 minutes once weekly for 7 weeks followed by a one-week rest, then once weekly for 3 consecutive weeks every 28-days in subsequent cycles (n=63) or fluorouracil 600 mg/m2 intravenously over 30 minutes once weekly (n=63). In Study 6, all patients received gemcitabine 1000 mg/m2 intravenously over 30 minutes once weekly for 7 weeks followed by a one-week rest, then once weekly for 3 consecutive weeks every 28-days in subsequent cycles.

    The major efficacy outcome measure in both trials was “clinical benefit response”. A patient was considered to have had a clinical benefit response if either of the following occurred:

    • The patient achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card) or analgesic consumption, or a 20-point or greater improvement in performance status (Karnofsky Performance Status) for a period of at least 4 consecutive weeks, without showing any sustained worsening in any of the other parameters. Sustained worsening was defined as 4 consecutive weeks with either any increase in pain intensity or analgesic consumption or a 20-point decrease in performance status occurring during the first 12 weeks of therapy.

      OR

    • The patient was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation.

    Study 5 enrolled 126 patients. Demographics and baseline characteristics were similar between the arms (Table 22).

    The efficacy results are shown in Table 23 and Figure 4. Patients treated with gemcitabine had statistically significant increases in clinical benefit response, survival, and time to disease progression compared to those randomized to receive fluorouracil. No confirmed objective tumor responses were observed in either treatment arm.

    Table 22: Baseline Demographics and Clinical Characteristics for Study 5

    Gemcitabine 
    (N=63)

    Fluorouracil
    (N=63)

    Male

    54%

    54%

    Median age, years

    62

    61

    Range

    37 to 79

    36 to 77

    Stage IV disease

    71%

    76%

    Baseline KPSa ≤70

    70%

    68%

    a Karnofsky Performance Status.

     

    Table 23: Efficacy Results in Study 5

    Efficacy Parameter

    Gemcitabine
    (N=63)

    Fluorouracil
    (N=63)

    Clinical Benefit Response

    p-valuea

    22.2%

    4.8%

    p=0.004

    Overall Survival

    Median (95% CI) in months

    5.7 (4.7, 6.9)

    4.2 (3.1, 5.1)

    p-valuea

    p=0.0009

    Time to Disease Progression

    Median (95% CI) in months

    2.1 (1.9, 3.4)

    0.9 (0.9, 1.1)

    p-valuea

    p=0.0013

    a p-value for clinical benefit response calculated using the two-sided test for difference in binomial proportions. All other p-values are calculated using log rank test.

    Figure 4: Kaplan-Meier Curves for Overall Survival in Study 5

    e6d71634-figure-05
  • 15 REFERENCES

    1. OSHA Hazardous Drugs.” OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html
  • 16  HOW SUPPLIED/STORAGE AND HANDLING

    Gemcitabine Injection is available in sterile single-dose vials individually packaged in a carton as follows:

    • 200 mg/5.26 mL (38 mg/mL), sterile solution in a single-dose glass vialper package, NDC: 45963-623-57
    • 1 g/26.3 mL (38 mg/mL), sterile solution in a single-dose glass vial per package, NDC: 45963-624-58
    • 2 g/52.6 mL (38 mg/mL), sterile solution in a single-dose glass vial per package, NDC: 45963-636-60

    Unopened vials of Gemcitabine Injection are stable until the expiration date indicated on the package when stored at 2° to 8°C (36° to 46°F). Do not freeze [see Dosage and Administration (2.6)].

    Gemcitabine Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.1

    This vial stopper is not made with natural rubber latex.

    Sterile, Nonpyrogenic, Preservative-free.

  • 17  PATIENT COUNSELING INFORMATION

    Myelosuppression

    Advise patients of the risks of myelosuppression. Instruct patients to immediately contact their healthcare provider should any signs or symptoms of infection, including fever, or if bleeding, or signs of anemia, occur [see Warnings and Precautions (5.2)].

    Pulmonary Toxicity

    Advise patients of the risks of pulmonary toxicity including respiratory failure and death. Instruct patients to immediately contact their healthcare provider for development of shortness of breath, wheezing, or cough [see Warnings and Precautions (5.3)].

    Hemolytic Uremic Syndrome and Renal Failure

    Advise patients of the risks of hemolytic uremic syndrome and associated renal failure. Instruct patients to immediately contact their healthcare provider for changes in the color or volume of urine output or for increased bruising or bleeding [see Warnings and Precautions (5.4)].

    Hepatic Toxicity

    Advise patients of the risks of hepatic toxicity including liver failure and death. Instruct patients to immediately contact their healthcare provider for signs of jaundice or for pain/tenderness in the right upper abdominal quadrant [see Warnings and Precautions (5.5)].

    Embryo-Fetal Toxicity

    Advise females and males of reproductive potential that gemcitabine injection can cause fetal harm. Advise females of reproductive potential to use effective contraception during treatment with gemcitabine injection and for 6 months after the final dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with gemcitabine injection and for 3 months after the final dose [see Warnings and Precautions (5.6), Use in Specific Populations (8.1, 8.3)].

    Lactation

    Advise women not to breastfeed during treatment with gemcitabine injection and for at least one week after the last dose [see Use in Specific Populations (8.2)].

    Infertility

    Advise males of reproductive potential of the potential for reduced fertility with gemcitabine injection [see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1)].

    Made in Italy

    Distributed by:
    Actavis Pharma, Inc.
    Parsippany, NJ 07054 USA

    Rev. A 6/2019

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Actavis

    NDC: 45963-623-57

    Gemcitabine Injection

    200 mg/5.26 mL

    (38 mg/mL)

    For Intravenous Infusion Only
    Must Be Diluted Before Use
    Store at 2° to 8°C (36° to 46°F).
    Discard Unused Portion.

    CAUTION: Cytotoxic Agent

    Single-Use Vial

    1
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Actavis

    NDC: 45963-624-58

    Gemcitabine Injection

    1 g/26.3 mL

    (38 mg/mL)

    For Intravenous Infusion Only
    Must Be Diluted Before Use
    Store at 2° to 8°C (36° to 46°F).
    Discard Unused Portion.

    CAUTION: Cytotoxic Agent

    Single-Use Vial

    1
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Actavis

    NDC: 45963-636-60

    Gemcitabine Injection

    2 g/52.6 mL

    (38 mg/mL)

    For Intravenous Infusion Only
    Must Be Diluted Before Use
    Store at 2° to 8°C (36° to 46°F).
    Discard Unused Portion.

    CAUTION: Cytotoxic Agent

    Single-Use Vial

    1

  • INGREDIENTS AND APPEARANCE
    GEMCITABINE 
    gemcitabine injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 45963-623
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    GEMCITABINE HYDROCHLORIDE (UNII: U347PV74IL) (GEMCITABINE - UNII:B76N6SBZ8R) GEMCITABINE38 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 45963-623-571 in 1 CARTON04/12/2016
    126.3 mL in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20454904/12/2016
    GEMCITABINE 
    gemcitabine injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 45963-624
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    GEMCITABINE HYDROCHLORIDE (UNII: U347PV74IL) (GEMCITABINE - UNII:B76N6SBZ8R) GEMCITABINE38 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 45963-624-581 in 1 CARTON04/12/2016
    152.6 mL in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20454904/12/2016
    GEMCITABINE 
    gemcitabine injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 45963-636
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    GEMCITABINE HYDROCHLORIDE (UNII: U347PV74IL) (GEMCITABINE - UNII:B76N6SBZ8R) GEMCITABINE38 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 45963-636-601 in 1 CARTON04/12/2016
    15.26 mL in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20454904/12/2016
    Labeler - Actavis Pharma, Inc. (119723554)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.